1
|
Garot P, Brunel P, Dibie A, Morelle JF, Abdellaoui M, Levy R, Carrié D, Karsenty B, Robin C, Berland J, Copt S, Sadozai Slama S, Oldroyd K, Morice MC, Lipiecki J. Comparison of outcomes in patients with or without ARC-HBR criteria undergoing PCI with polymer-free biolimus coated stents: The BioFreedom France study. Catheter Cardiovasc Interv 2023; 101:60-71. [PMID: 36378683 DOI: 10.1002/ccd.30481] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/22/2022] [Revised: 08/12/2022] [Accepted: 11/02/2022] [Indexed: 11/17/2022]
Abstract
BACKGROUND The polymer-free biolimus coated stent (BioFreedom) was shown to be superior to bare metal stents in the LEADERS FREE randomized trial in high bleeding risk (HBR) patients treated with 1-month dual antiplatelet therapy (DAPT). However, there is limited outcome data with this device in an all-comers' population. METHODS We conducted a prospective single-arm study of patients undergoing percutaneous coronary intervention with the polymer-free biolimus coated stent in 25 centers in France with wide inclusion criteria including multivessel disease, complex lesions, and acute coronary syndromes. The primary endpoint was the incidence of target lesion failure (TLF), a composite of cardiac death or target-vessel myocardial infarction (MI) or clinically indicated target lesion revascularization (ci-TLR) at 1-year. The patient population was classified according to the presence (or not) of HBR criteria according to the recent ARC-HBR definition. RESULTS Between April 2019 and April 2020, 1497 patients were enrolled. TLF occurred in 101 (6.9%) patients, including cardiac death in 35 (2.4%), target vessel MI in 20 (1.4%) and ci-TLR in 65 (4.5%) of them. There were 491 HBR patients (32.8%) and 1006 non-HBR patients. The median duration of DAPT was 74 days in the HBR group versus 348 days in the non-HBR group (p < 0.0001). TLF occurred in 44 (9.2%) of the HBR group and in 57 (5.8%) of the non-HBR group (relative risk 1.62 [95% confidence interval: 1.10-2.41], p = 0015). Compared to the non-HBR group, HBR patients had higher rates of cardiac death (4.4% vs. 1.4%, p = 0.0005) and target vessel MI (2.9% vs. 0.6%, p = 0.0003), but similar rates of ci-TLR. BARC 3-5 bleeding occurred in 6.2% of the HBR group versus 1.4% of the non-HBR group (p < 0.0001). CONCLUSION In this multicenter all-comers study, HBR patients treated with a polymer-free biolimus coated stent had, compared to non-HBR patients, an increased risk of cardiac death and MI, and despite a shorter duration of DAPT, continued to have higher rates of BARC 3-5 bleeding.
Collapse
Affiliation(s)
- Philippe Garot
- Institut Cardiovasculaire Paris-Sud (ICPS), Hôpital Privé Jacques Cartier, Ramsay-Santé, Massy, France
| | - Philippe Brunel
- Institut Cardio-Vasculaire Dijon Bourgogne, Hôpital Privé Dijon Bourgogne, Ramsay-Santé, Dijon, France
| | - Alain Dibie
- Institut Mutualiste Montsouris, Paris, France
| | | | | | - Raphy Levy
- Hôpital Privé Saint-Martin, ELSAN, Bordeaux, France
| | | | | | | | | | - Samuel Copt
- Biosensors International, Morges, Switzerland
| | | | | | - Marie-Claude Morice
- Institut Cardiovasculaire Paris-Sud (ICPS), Hôpital Privé Jacques Cartier, Ramsay-Santé, Massy, France
- Centre Européen de Recherche Cardiovasculaire (CERC), Ramsay-Santé, Massy, France
| | - Janusz Lipiecki
- Clinique des Domes, Pole Santé République, ELSAN, Clermont-Ferrand, France
| |
Collapse
|
2
|
Eberli FR, Stoll HP, Urban P, Morice MC, Brunel P, Maillard L, Lipiecki J, Cook S, Berland J, Hovasse T, Carrie D, Schütte D, Slama SS, Garot P. Polymer-free Biolimus-A9 coated thin strut stents for patients at high bleeding risk 1-year results from the LEADERS FREE III study. Catheter Cardiovasc Interv 2021; 99:593-600. [PMID: 34241947 PMCID: PMC9544800 DOI: 10.1002/ccd.29869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/04/2021] [Revised: 06/14/2021] [Accepted: 07/01/2021] [Indexed: 11/11/2022]
Abstract
BACKGROUND In patients at high bleeding risk (HBR), the LEADERS FREE (LF) trial established the safety and efficacy of a polymer-free drug coated (Biolimus-A9) stainless steel stent (SS-DCS) with 30 days of dual antiplatelet treatment (DAPT). In LEADERS FREE III, we studied a new cobalt-chromium thin-strut stent (CoCr-DCS) in HBR patients. METHODS The CoCr-DCS shares all of the design features of the SS-DCS but has a CoCr stent platform with strut thickness of 84-88 μm. The primary safety endpoint was a composite of cardiac death, myocardial infarction (MI), and definite/probable stent thrombosis. The primary efficacy endpoint was clinically indicated target lesion revascularization. Outcomes were compared to those of LF (non-inferiority to SS-DCS for safety and superiority to SS-BMS for efficacy). Additional propensity-matched comparisons were performed to account for baseline differences. RESULTS We recruited 401 HBR patients using identical criteria to the LF trial. At 1 year, the primary safety endpoint was reached by 31/401 (8.0%) of patients treated with the CoCr-DCS versus 35/401 (8.9%) for the propensity-matched cohort (HR: 0.89, [0.55-1.44], p < 0.001 for non-inferiority, 0.62 for superiority). The efficacy endpoint was reached by 16/401 (4.2%) of CoCr-DCS patients versus 41/401 (10.6%) in the propensity-matched cohort (HR: 0.4 [0.2:0.7]) (p = 0.007 for superiority). There was no statistical difference between CoCr-DCS and SS-DCS in terms of efficacy (HR: 1.46 [0.68-3.15], p = 0.33). CONCLUSIONS The new thin-strut CoCr-DCS proved non-inferior to the SS-DCS for safety, and superior to the BMS for efficacy in HBR patients treated with 30 days of DAPT.
Collapse
Affiliation(s)
- Franz R Eberli
- Cardiology Department, Triemli Hospital, Zurich, Switzerland
| | - Hans-Peter Stoll
- Clinical Research, Biosensors Clinical Research, Morges, Switzerland
| | - Philip Urban
- Cardiovascular European Research Center (CERC), Massy, France
| | | | - Philippe Brunel
- Interventional Cardiology Unit, Clinique de Fontaine, Dijon, France
| | - Luc Maillard
- Department of Cardiology, GCS ES Axium-Rambot, Aix-en-Provence, France
| | - Janus Lipiecki
- Department of Cardiology, Pole Sante Republique, Clermont Ferrand, France
| | - Stephane Cook
- Department of Cardiology, University Hospital Fribourg, Fribourg, Switzerland
| | - Jacques Berland
- Department of Cardiology, Clinique Saint Hilaire, Rouen, France
| | - Thomas Hovasse
- Department of Cardiology, Institut Cardiovasculaire Paris-Sud (ICPS), Ramsay-Santé, Hôpital Jacques Cartier, Massy, France
| | - Didier Carrie
- Cardiology Department, Centre Hospitalier Universitaire Rangueil, Toulouse, France
| | - Diana Schütte
- Clinical Research, Biosensors Clinical Research, Morges, Switzerland
| | | | - Philippe Garot
- Ramsay-Santé, Hôpital Claude Galien, Institut Cardiovasculaire Paris-Sud (ICPS), Quincy, France
| |
Collapse
|
3
|
Marquis-Gravel G, Urban P, Copt S, Capodanno D, Pocock S, Sadozai Slama S, Stoll HP, Tanguay JF, Mehran R, Leon MB, Rao S, Morice MC, Krucoff MW. Drug-coated stents versus bare metal stents in Academic Research Consortium-defined high bleeding risk patients. EUROINTERVENTION 2021; 17:240-247. [PMID: 32830645 PMCID: PMC9724924 DOI: 10.4244/eij-d-20-00749] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
BACKGROUND More effective and progressively safer generations of drug-elut-ing stents (DES) have replaced bare metal stents (BMS) in rou-tine clinical practice. However, patients considered to be at high bleeding risk (HBR) have traditionally been underrepresented in pivotal DES trials. AIMS The aim of this study was to model the safety and effectiveness of drug-coated stents (DCS) versus BMS in HBR patients according to the Academic Research Consortium (ARC) criteria. METHODS Participants from the LEADERS FREE (LF) and LEADERS FREE II (LFII) studies were pooled into one data set. Participants were treated with 30 days of DAPT. The primary safety (composite of cardiac death, myocardial infarction, or stent thrombosis) and effectiveness (target lesion revascularisation) endpoints were compared between DCS and BMS in the subgroup of patients satisfying the ARC-HBR definition using propensity-score modelling. RESULTS From the 3,635 participants included in the combined LF and LFII data set, 2,898 (79.7%) satisfied the ARC-HBR criteria (DCS: 1,923; BMS: 975). The primary safety endpoint occurred in 184 (9.8%) and in 132 (13.8%) participants in the DCS and BMS groups, respectively (adjusted HR 0.72, 95% CI: 0.57-0.91; p=0.006). The risk of the primary effectiveness endpoint was also significantly lower with DCS (6.2%) versus BMS (8.8%) (adjusted HR 0.70, 95% CI: 0.52-0.94; p=0.016). The safety and effectiveness of DCS versus BMS were consistent according to ARC-HBR status (p for interaction=0.206 and 0.260, respectively). CONCLUSIONS DCS are safer and more effective than BMS in an ARC-defined HBR population.
Collapse
Affiliation(s)
| | | | | | - Davide Capodanno
- Cardiovascular Department, Ferrarotto Hospital, University of Catania, and ETNA Foundation, Catania, Italy
| | - Stuart Pocock
- Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom
| | | | | | - Jean-François Tanguay
- Montreal Heart Institute, Department of Medicine, Université de Montréal, Montréal, QC, Canada
| | - Roxana Mehran
- The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, and the Clinical Trials Center, Cardiovascular Research Foundation, New York, NY, USA
| | - Martin B. Leon
- Division of Cardiology, Columbia University Medical Center, New York, NY, USA
| | - Sunil Rao
- Duke Clinical Research Institute, Durham, NC, USA,Duke University School of Medicine, Durham, NC, USA
| | - Marie-Claude Morice
- Ramsay Générale de Santé - Institut Cardiovasculaire Paris Sud, Massy, France
| | | |
Collapse
|
4
|
Alexander Menown IB, Mamas M, Cotton J, Hildick-Smith D, Eberli F, Leibundgut G, Tresukosol D, Macaya C, Copt S, Slama SS, Oldroyd K. TCT CONNECT-266 Cobalt Chromium Biolimus Drug-Eluting Stents Compared With Stainless Steel Biolimus Drug-Eluting Stents: Final Results of BMX Alpha. J Am Coll Cardiol 2020. [DOI: 10.1016/j.jacc.2020.09.283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
5
|
Marquis-Gravel G, Urban PM, Copt S, Slama SS, Stoll HP, Mehran R, Capodanno D, Leon M, Rao S, Pocock S, Morice M, Krucoff M. EVALUATION OF THE ACADEMIC RESEARCH CONSORTIUM HIGH BLEEDING RISK DEFINITION IN PATIENTS TREATED WITH DRUG-COATED STENTS AND BARE-METAL STENTS FROM THE LEADERS FREE I & II TRIALS. J Am Coll Cardiol 2020. [DOI: 10.1016/s0735-1097(20)32129-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|